摘要
目的观察不同剂量奥沙利铂联合介入治疗在肝癌患者中的应用效果。方法选取自2017年1月至2019年6月至濮阳市油田总医院治疗的肝癌患者120例。按照随机数表法将其随机分为高剂量组和低剂量组,每组分别60例患者。其中,通过介入治疗的方法对高剂量组患者注射60 mg/m^2奥沙利铂,对低剂量组患者注射30 mg/m^2奥沙利铂,比较两组患者近期疗效、治疗后不良反应和治疗后血液生化指标。结果高剂量组总有效率为78.33%,低剂量组总有效率为83.33%,两组患者近期疗效的总有效率值比较,差异无统计学意义(P>0.05);两组患者过敏、贫血、周围神将突变现象的概率差异均无统计学意义(P>0.05);低剂量组患者的恶心呕吐以及疼痛分别占16.67%和20.00%,明显低于高剂量组,组间对比差异有统计学意义(P<0.01)。两组患者血液中WBC含量高剂量组[(4.21±1.59)×10^9/L]低于低剂量组,差异有统计学意义(P<0.01);ALT含量高剂量组[(77.03±22.92)U/L]高于低剂量组[(46.03±21.75)U/L],差异有统计学意义(P<0.01)。两组患者血液中AST、TBIL含量对比,差异均无统计学意义(P>0.05)。高剂量组两组患者1年、2年后的生存状况比较,差异均无统计学意义(P>0.05)。结论用低剂量奥沙利铂联合介入治疗对肝癌患者进行治疗,患者治疗后的不良反应轻,且对患者生存无影响,值得临床推广应用。
Objective To explore the effect of different doses of oxaliplatin combined with interventional therapy in patients with liver cancer.Methods Totally 120 patients with hepatocellular carcinoma treated in our hospital from January 2017 to June 2019 were selected.They were randomly divided into high dose group and low dose group according to the random number table method,each group of 60 patients.Among them,60 mg/m^2 oxaliplatin was injected into the high dose group and 30 mg/m^2 oxaliplatin was injected into the dose group.The adverse effects of the two groups were compared,the adverse reactions after treatment and the blood biochemical indexes after treatment.Results There was no significant difference in the total effective rate between the two groups(P>0.05).The adverse reactions of nausea and vomiting and pain were significantly lower in the two groups than those in the high dose group,the difference was statistically significant(P<0.01).The detection of blood biochemical indexes after treatment showed that there was no significant difference in the probability of allergy,anemia and peripheral neurons in the two groups(P>0.05).The high dose of WBC in the patients was significantly lower than that in the low dose group(P<0.01).There was significant difference between the high dose group and the low dose group of ALT(P<0.05).The difference was statistically significant(P<0.05).Conclusion Low dose of oxaliplatin is used to treat patients with hepatocellular carcinoma.The adverse reactions after treatment are mild and have no effect on the survival of patients.It is worthy of clinical application.
作者
史辰涛
SHI Chen-tao(Puyang Oilfield General Hospital,Puyang,Henan 457001,China)
出处
《医药论坛杂志》
2020年第9期62-65,共4页
Journal of Medical Forum
关键词
奥沙利铂
肝癌
联合介入治疗
Oxaliplatin
Liver cancer
Interventional therapy
Combined intervention
